

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



10/528021



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024883 A2

- (51) International Patent Classification⁷: C12N
- (21) International Application Number: PCT/US2003/028904
- (22) International Filing Date: 15 September 2003 (15.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/410,986 16 September 2002 (16.09.2002) US
- (71) Applicant (for all designated States except US): EX-ELIXIS, INC. [US/US]; P.O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): FRANCIS-LANG, Helen [GB/US]; 1782 Pacific Avenue, Apt. 2, San Francisco, CA 94109 (US). ROCHE, Siobhan [IE/IE]; 30 Moatfield Park, Coolock, Dublin 5 (IE). LICKTEIG, Kim [US/US]; 1921 Grove Street, San Francisco, CA 94117 (US).
- (74) Agents: SHAYESTEH, Laleh et al.; Exelixis, Inc., P.O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE

(57) Abstract: Human PAK genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of PAK are provided.

WO 2004/024883 A2

PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE

REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent application 60/410,986
5 filed 9/16/2002. The contents of the prior application are hereby incorporated in their
entirety.

BACKGROUND OF THE INVENTION

The integrity of the genome is monitored by cell cycle checkpoints that, in
10 response to DNA damage, delay progression through the cell cycle until the damage has
been repaired. Chk1 kinase is an essential component of the G2 DNA damage checkpoint
(Liu et. al. Genes Dev (2000) 14:1448-1459, Takai et. al. Genes Dev (2000) 14:1439-
1447). Specifically, Chk1 is activated by the DNA damage sensor, ATR, and the
checkpoint Rad proteins in response to genotoxic stress. The direct downstream target of
15 the Chk1 kinase is the Cdc25C phosphatase (Sanchez et. al. Science (1997) 277:1497-
1501). Cdc25C promotes progression through the G2/M phase of the cell cycle by
removing the inhibitory phosphate groups (Thr14 and Tyr15) from Cdc2, the cyclin-
dependent kinase that promotes mitosis when bound to cycB. Phosphorylation of Cdc25C
by Chk1 directly inhibits its phosphatase activity and creates a binding site for 14-3-3
20 proteins resulting in its export from the nucleus (Peng et. al. Science (1997) 277:1501-
1505). The result of the inhibitory phosphorylation of Cdc25C is that Cdc2/cycB remains
in the inactive phosphorylated state and a G2 cell cycle arrest occurs.

Chk1 can also cause a G1 cell cycle arrest or apoptosis by phosphorylating and
stabilizing p53 (Shieh et. al. Genes Dev. (2000)14:289-300, Chehab et. al. Genes Dev.
25 (200)14, 278-288). The p53 gene is one of the most commonly found mutations in cancer
cells and is an essential component of the G1 cell cycle checkpoint (Levine Cell (1997)
88:323-331; Hollstein et. al. Nucleic Acids Res. (1994) 22:3551-3555). Indeed, more
than 90% of solid tumors contain a defective G1 DNA damage checkpoint. Studies have
shown that p53-deficient tumor cells are more susceptible to the cytotoxic effects of DNA
30 damaging agents if the G2 checkpoint is also disrupted by inhibiting either ATR or Chk1
(Nghiem et. al. PNAS (2001) 98:9092-9097, Suganuma et. al. Cancer Res (1999) 59:5887-
5891). The Chk1 kinase inhibitor, UCN-01 is currently undergoing clinical trials as a
modulator of anti-cancer drug sensitivity (Busby et. al. Cancer Res (2000) 60:2108-2102).
Therefore, other essential components of the G2 DNA damage checkpoint may also be

effective drug targets for selectively killing G1 checkpoint defective cancer cells is response to chemotherapeutic DNA damaging agents. Chk1 sequences are highly conserved in evolution, and have been identified in a number of organisms including yeast (Walworth, N., et al (1993) Nature 363: 368-371), *Drosophila* (Fogarty, P., et al. (1997) Curr. Biol. 7: 418-426), mouse (Sanchez, Y., et al (1997) Science 277:1497-1501), and human (Sanchez, Y., et al (1997) Science 277:1497-1501), among others.

p21 (CDKN1A)-activated kinases, or PAKs, bind to and are activated by Rho family GTPases, such as CDC42 and RAC. PAK proteins are highly conserved in their amino acid sequence, are related to yeast STE20, and have been implicated as critical downstream effectors that link Rho GTPases to the actin cytoskeleton and to MAP kinase cascades, including the JUN N-terminal kinase (JNK) and p38.

PAK1 (p21/CDC42/RAC1-activated kinase 1) is believed to act directly on the JNK1 MAP kinase pathway, and its activity is induced by coexpression with RAC1 or CDC42. PAK1 protein promotes the disassembly of stress fibers and focal adhesions, and may regulate cytoskeletal dynamics (Sanders, L. C et al (1999) Science 283: 2083-2085).

The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene

implicated in a disease pathway, such as CHK, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in their entireties.

SUMMARY OF THE INVENTION

We have discovered genes that modify the CHK pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as p21/CDC42/RAC1-activated kinase (PAK). The invention provides methods for utilizing these CHK modifier genes and polypeptides to identify PAK-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired CHK function and/or PAK function. Preferred PAK-modulating agents specifically bind to PAK polypeptides and restore CHK function. Other preferred PAK-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress PAK gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

PAK modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with a PAK polypeptide or nucleic acid. In one embodiment, candidate PAK modulating agents are tested with an assay system comprising a PAK polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate CHK modulating agents. The assay system may be cell-based or cell-free. PAK-modulating agents include PAK related proteins (e.g. dominant negative mutants, and biotherapeutics); PAK -specific antibodies; PAK -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with PAK or compete with PAK binding partner (e.g. by binding to a PAK binding partner). In one specific embodiment, a small molecule modulator is identified using a kinase assay. In specific embodiments, the screening assay system is selected from a binding assay, an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

In another embodiment, candidate CHK pathway modulating agents are further tested using a second assay system that detects changes in the CHK pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified

candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the CHK pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the PAK function and/or the CHK pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a PAK polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated the CHK pathway.

DETAILED DESCRIPTION OF THE INVENTION

Genetic screens were designed to identify modifiers of the Chk1 pathway in *Drosophila*, where the Chk1 gene was overexpressed specifically in the eye, resulting in a G2 cell cycle arrest and a deterioration of general eye morphology. The screen was designed to identify suppressors and enhancers of *Drosophila* Chk1. The fly chk1 gene was identified as a modifier of the CHK pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, PAK genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective CHK signaling pathway, such as cancer.

In vitro and in vivo methods of assessing PAK function are provided herein. Modulation of the PAK or their respective binding partners is useful for understanding the association of the CHK pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for CHK related pathologies. PAK-modulating agents that act by inhibiting or enhancing PAK expression, directly or indirectly, for example, by affecting a PAK function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. PAK modulating agents are useful in diagnosis, therapy and pharmaceutical development.

Nucleic acids and polypeptides of the invention

Sequences related to PAK nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) number) as GI#s 7382495 (SEQ ID NO:1), 20483033 (SEQ ID NO:2), 3265159 (SEQ ID NO:3),

16549911 (SEQ ID NO:4), 1256421 (SEQ ID NO:5), and 18577341 (SEQ ID NO:6) for nucleic acid, and GI# 7382496 (SEQ ID NO:7) for polypeptides.

The term "PAK polypeptide" refers to a full-length PAK protein or a functionally active fragment or derivative thereof. A "functionally active" PAK fragment or derivative

5 exhibits one or more functional activities associated with a full-length, wild-type PAK protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of PAK proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current

10 Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active PAK polypeptide is a PAK derivative capable of rescuing defective endogenous PAK activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of a PAK, such as a

15 kinase domain or a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). For example, the kinase domain (PFAM 00069) of PAK from GI# 7382496 (SEQ ID NO:7) is located at approximately amino acid residues 270 to 521. Methods for obtaining PAK polypeptides are also further described below. In some embodiments, preferred fragments are

20 functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of SEQ ID NO:7 (a PAK). In further preferred embodiments, the fragment comprises the entire kinase (functionally active) domain.

The term "PAK nucleic acid" refers to a DNA or RNA molecule that encodes a

25 PAK polypeptide. Preferably, the PAK polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human PAK. Methods of identifying orthologs are known in the art. Normally, orthologs in different species retain

30 the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad

Sci (1998) 95:5849-5856; Huynen MA *et al.*, Genome Research (2000) 10:1204-1210).

Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD *et al.*, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or

residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree

5 representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences,

Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene

10 duplication event follows speciation, a single gene in one species, such as *Drosophila*, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative

15 sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the

20 same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the

30 protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and

histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, *Advances in Applied Mathematics* 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, *J. of Molec.Biol.*, 147:195-197; Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, *Genomics* 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 *Nucl. Acids Res.* 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of SEQ ID NOs:1-6. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*, *Current Protocol in Molecular Biology*, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook *et al.*, *Molecular Cloning*, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of any one of SEQ ID NOs:1-6 under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1%

Ficoll, 1% BSA, and 500 $\mu\text{g/ml}$ denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% FVP, 0.02% Ficoll, 0.2% BSA, 100 $\mu\text{g/ml}$ salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution
5 containing 2X SSC and 0.1% SDS.

Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 $\mu\text{g/ml}$ denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20
10 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

Isolation, Production, Expression, and Mis-expression of PAK Nucleic Acids and Polypeptides

PAK nucleic acids and polypeptides are useful for identifying and testing agents
15 that modulate PAK function and for other applications related to the involvement of PAK in the CHK pathway. PAK nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the
20 protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may
25 require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of a PAK protein for assays used to assess PAK function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be
30 used (*e.g.*, Higgins SJ and Hames BD (eds.) Protein Expression: A Practical Approach, Oxford University Press Inc., New York 1999; Stanbury PF et al., Principles of Fermentation Technology, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) Protein Purification Protocols, Humana Press, New Jersey, 1996; Coligan JE et al, Current Protocols in Protein Science (eds.), 1999, John Wiley & Sons, New York). In particular

embodiments, recombinant PAK is expressed in a cell line known to have defective CHK function. The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

5 The nucleotide sequence encoding a PAK polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native PAK gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus);
10 microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the PAK gene product, the expression vector can comprise a promoter operably linked to a PAK gene nucleic acid, one or more origins of replication,
15 and, one or more selectable markers (*e.g.* thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the PAK gene product based on the physical or functional properties of the PAK protein in *in vitro* assay systems (*e.g.* immunoassays).

The PAK protein, fragment, or derivative may be optionally expressed as a fusion,
20 or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques,
25 *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

Once a recombinant cell that expresses the PAK gene sequence is identified, the gene product can be isolated and purified using standard methods (*e.g.* ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native PAK proteins can be purified from natural sources,
30 by standard methods (*e.g.* immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of PAK or other genes associated with the CHK

pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (e.g. by gene knock-out or blocking expression that would otherwise normally occur).

5 Genetically modified animals

Animal models that have been genetically modified to alter PAK expression may be used in *in vivo* assays to test for activity of a candidate CHK modulating agent, or to further assess the role of PAK in a CHK pathway process such as apoptosis or cell proliferation. Preferably, the altered PAK expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal PAK expression. The genetically modified animal may additionally have altered CHK expression (e.g. CHK knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sanford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830; for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer *et al.*, Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods

such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) Nature 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous PAK gene that results in a decrease of PAK function, preferably such that PAK expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse PAK gene is used to construct a homologous recombination vector suitable for altering an endogenous PAK gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner *et al.*, Nature (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, Science (1989) 244:1281-1288; Simms *et al.*, Bio/Technology (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH *et al.*, (1994) Scan J Immunol 40:257-264; Declerck PJ *et al.*, (1995) J Biol Chem. 270:8397-400).

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the PAK gene, e.g., by introduction of additional copies of PAK, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the PAK gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*,

PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) Nat Genet 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the CHK pathway, as animal models of disease and disorders implicating defective CHK function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered PAK function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered PAK expression that receive candidate therapeutic agent.

In addition to the above-described genetically modified animals having altered PAK function, animal models having defective CHK function (and otherwise normal PAK function), can be used in the methods of the present invention. For example, a CHK knockout mouse can be used to assess, *in vivo*, the activity of a candidate CHK modulating agent identified in one of the *in vitro* assays described below. Preferably, the candidate CHK modulating agent when administered to a model system with cells defective in CHK function, produces a detectable phenotypic change in the model system indicating that the CHK function is restored, i.e., the cells exhibit normal cell cycle progression.

Modulating Agents

The invention provides methods to identify agents that interact with and/or modulate the function of PAK and/or the CHK pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the CHK pathway, as well as in further analysis of the PAK protein and its contribution to the CHK pathway.

Accordingly, the invention also provides methods for modulating the CHK pathway comprising the step of specifically modulating PAK activity by administering a PAK-interacting or -modulating agent.

As used herein, an "PAK-modulating agent" is any agent that modulates PAK function, for example, an agent that interacts with PAK to inhibit or enhance PAK activity or otherwise affect normal PAK function. PAK function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a preferred embodiment, the PAK - modulating agent specifically modulates the function of the PAK. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the PAK polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the PAK. These phrases also encompass modulating agents that alter the interaction of the PAK with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of a PAK, or to a protein/binding partner complex, and altering PAK function). In a further preferred embodiment, the PAK- modulating agent is a modulator of the CHK pathway (e.g. it restores and/or upregulates CHK function) and thus is also a CHK-modulating agent.

Preferred PAK-modulating agents include small molecule compounds; PAK-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19th edition.

Small molecule modulators

Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or

identified based on known or inferred properties of the PAK protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for PAK-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the CHK pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

Specific PAK-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the CHK pathway and related disorders, as well as in validation assays for other PAK-modulating agents. In a preferred embodiment, PAK-interacting proteins affect normal PAK function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, PAK-interacting proteins are useful in detecting and providing information about the function of PAK proteins, as is relevant to CHK related disorders, such as cancer (e.g., for diagnostic means).

A PAK-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with a PAK, such as a member of the PAK pathway that modulates PAK expression, localization, and/or activity. PAK-modulators include dominant negative forms of PAK-interacting proteins and of PAK proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous PAK-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford,

England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).

A PAK-interacting protein may be an exogenous protein, such as a PAK-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). PAK antibodies are further discussed below.

In preferred embodiments, a PAK-interacting protein specifically binds a PAK protein. In alternative preferred embodiments, a PAK-modulating agent binds a PAK substrate, binding partner, or cofactor.

Antibodies

In another embodiment, the protein modulator is a PAK specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify PAK modulators. The antibodies can also be used in dissecting the portions of the PAK pathway responsible for various cellular responses and in the general processing and maturation of the PAK.

Antibodies that specifically bind PAK polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of PAK polypeptide, and more preferably, to human PAK. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of PAK which are particularly antigenic can be selected, for example, by routine screening of PAK polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Natl. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence shown in SEQ ID NO:7. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press,

New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of PAK or substantially purified fragments thereof. If PAK fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of a PAK protein. In a particular embodiment, PAK-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

The presence of PAK-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding PAK polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

Chimeric antibodies specific to PAK polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

PAK-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No.

4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve *in vitro* exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml.

Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Nucleic Acid Modulators

5 Other preferred PAK-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit PAK activity. Preferred nucleic acid modulators interfere with the function of the PAK nucleic acid such as DNA replication, transcription, translocation of the PAK RNA to the site of protein translation, translation of protein from the PAK RNA, splicing of the PAK RNA to
10 yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the PAK RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to a PAK mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. PAK-specific antisense oligonucleotides, preferably range
15 from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified
20 at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of
25 which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton
30 J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

Alternative preferred PAK nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded

RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498).

Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, et al, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36:1923-1937; Tonkinson JL et al., Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65). Accordingly, in one aspect of the invention, a PAK-specific nucleic acid modulator is used in an assay to further elucidate the role of the PAK in the CHK pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, a PAK-specific antisense oligomer is used as a therapeutic agent for treatment of CHK-related disease states.

Assay Systems

The invention provides assay systems and screening methods for identifying specific modulators of PAK activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the PAK nucleic acid or protein. In general, secondary assays further assess the activity of a PAK modulating agent identified by a primary assay and may confirm that the modulating agent

affects PAK in a manner relevant to the CHK pathway. In some cases, PAK modulators will be directly tested in a secondary assay.

In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising a PAK polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. kinase activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent modulates PAK activity, and hence the CHK pathway. The PAK polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

Primary Assays

The type of modulator tested generally determines the type of primary assay.

15 *Primary assays for small molecule modulators*

For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (e.g., receptor-ligand binding), transcriptional activity (e.g., using a reporter gene), enzymatic activity (e.g., via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

Cell-based screening assays usually require systems for recombinant expression of PAK and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain

their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein protein interactions and elucidation of protein complexes. In certain applications, when PAK-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the PAK protein may be assayed by various known methods such as substrate processing (e.g. ability of the candidate PAK-specific binding agents to function as negative effectors in PAK-expressing cells), binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), and immunogenicity (e.g. ability to elicit PAK specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a PAK polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The PAK polypeptide can be full length or a fragment thereof that retains functional PAK activity. The PAK polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The PAK polypeptide is preferably human PAK, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of PAK interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has PAK-specific binding activity, and can be used to assess normal PAK gene function.

Suitable assay formats that may be adapted to screen for PAK modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr Opin Biotechnol 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (e.g., Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451).

A variety of suitable assay systems may be used to identify candidate PAK and CHK pathway modulators (e.g. U.S. Pat. No. 6,165,992 (kinase assays); U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); and U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described
5 in more detail below.

Kinase assays. In some preferred embodiments the screening assay detects the ability of the test agent to modulate the kinase activity of a PAK polypeptide. In further embodiments, a cell-free kinase assay system is used to identify a candidate CHK
10 modulating agent, and a secondary, cell-based assay, such as an apoptosis or hypoxic induction assay (described below), may be used to further characterize the candidate CHK modulating agent. Many different assays for kinases have been reported in the literature and are well known to those skilled in the art (e.g. U.S. Pat. No. 6,165,992; Zhu et al., Nature Genetics (2000) 26:283-289; and WO0073469). Radioassays, which monitor the
15 transfer of a gamma phosphate are frequently used. For instance, a scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma phosphate from gamma -³³P ATP to a biotinylated peptide substrate; the substrate is captured on a streptavidin coated bead that transmits the signal (Beveridge M *et al.*, J Biomol Screen (2000) 5:205-212). This assay uses the scintillation proximity assay (SPA), in which only radio-ligand bound
20 to receptors tethered to the surface of an SPA bead are detected by the scintillant immobilized within it, allowing binding to be measured without separation of bound from free ligand.

Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates. For instance, the kinase receptor activation (KIRA)
25 assay measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, Dev Biol Stand (1999) 97:121-133).

Another example of antibody based assays for protein kinase activity is TRF (time-
30 resolved fluorometry). This method utilizes europium chelate-labeled anti-phosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using time-resolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., Anal Biochem 1996 Jul 1;238(2):159-64).

Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara *et al.*, 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo-ONE™ Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane breaks down, allowing for accumulation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. An apoptosis assay system may comprise a cell that expresses a PAK, and that optionally has defective CHK function (e.g. CHK is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate CHK modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate CHK modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether PAK function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express PAK relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the PAK plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, *Int. J. Cancer* 38, 369; Campana *et al.*, 1988, *J. Immunol. Meth.* 107, 79), or by other means.

Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specific to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee, D.N. 1995, *J. Biol. Chem* 270:20098-105). Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J., 1996, *Oncogene* 13:1395-403; Jeoung, J., 1995, *J. Biol. Chem.* 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA.

Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL *et al.*, 1998, *In Vitro Cell Dev Biol Anim* 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96[®] AQueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421).

Cell proliferation may also be assayed by colony formation in soft agar (Sambrook *et al.*, *Molecular Cloning*, Cold Spring Harbor (1989)). For example, cells transformed with PAK are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells. Such assays are commercially available, for example Cell Titer-Glo[™], which is a luminescent homogeneous assay available from Promega.

Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW *et al.* (1986) *Int J Radiat Biol Relat Stud Phys Chem Med* 49:237-55). Cells transfected with a PAK may be stained with propidium iodide and evaluated in a flow

cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses a PAK, and that optionally has defective CHK function (e.g. CHK is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate CHK modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate CHK modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether PAK function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express PAK relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the PAK plays a direct role in cell proliferation or cell cycle.

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses a PAK, and that optionally has defective CHK function (e.g. CHK is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate CHK modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate CHK modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether PAK function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express PAK relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the PAK plays a direct role in

angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays.

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia
5 inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in
vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be
important in tumour cell survival, such as those encoding glycolytic enzymes and VEGF.
Induction of such genes by hypoxic conditions may be assayed by growing cells
transfected with PAK in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance
10 N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions,
followed by assessment of gene activity or expression by Taqman®. For example, a
hypoxic induction assay system may comprise a cell that expresses a PAK, and that
optionally has defective CHK function (e.g. CHK is over-expressed or under-expressed
relative to wild-type cells). A test agent can be added to the hypoxic induction assay
15 system and changes in hypoxic response relative to controls where no test agent is added,
identify candidate CHK modulating agents. In some embodiments of the invention, the
hypoxic induction assay may be used as a secondary assay to test a candidate CHK
modulating agents that is initially identified using another assay system. A hypoxic
induction assay may also be used to test whether PAK function plays a direct role in the
20 hypoxic response. For example, a hypoxic induction assay may be performed on cells that
over- or under-express PAK relative to wild type cells. Differences in hypoxic response
compared to wild type cells suggests that the PAK plays a direct role in hypoxic induction.

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified
25 adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate
modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate
the adhesion of cells to purified proteins. For example, recombinant proteins are
produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The
wells used for negative control are not coated. Coated wells are then washed, blocked
30 with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration
and added to the blocked, coated wells. Cells are then added to the wells, and the unbound
cells are washed off. Retained cells are labeled directly on the plate by adding a
membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in
a fluorescent microplate reader.

Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells
5 expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay,
10 small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et
15 al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

Tubulogenesis. Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates
20 include MatrigelTM (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4° C and forms a solid gel at 37° C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally
25 be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed
30 with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF- α . Thus, in a further preferred embodiment, a

tubulogenesis assay system comprises testing a PAK's response to a variety of factors, such as FGF, VEGF, phorbol myristate acetate (PMA), TNF-alpha, ephrin, etc.

Cell Migration. An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, J Biol Chem 276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As described above, a preferred assay system for migration/invasion assays comprises testing a PAK's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

Sprouting assay. A sprouting assay is a three-dimensional *in vitro* angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). Spheroids are harvested and seeded in 900 μ l of methocel-collagen solution and pipetted

into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100 μ l of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting
5 intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

Primary assays for antibody modulators

For antibody modulators, appropriate primary assays test is a binding assay that
10 tests the antibody's affinity to and specificity for the PAK protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting PAK-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

15 In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

Primary assays for nucleic acid modulators

For nucleic acid modulators, primary assays may test the ability of the nucleic acid
20 modulator to inhibit or enhance PAK gene expression, preferably mRNA expression. In general, expression analysis comprises comparing PAK expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express PAK) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting,
25 ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that PAK mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001,
30 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the PAK protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve PAK mRNA expression, may also be used to test nucleic acid modulators.

5 **Secondary Assays**

Secondary assays may be used to further assess the activity of PAK-modulating agent identified by any of the above methods to confirm that the modulating agent affects PAK in a manner relevant to the CHK pathway. As used herein, PAK-modulating agents encompass candidate clinical compounds or other agents derived from previously
10 identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with PAK.

Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express PAK) in the
15 presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate PAK-modulating agent results in changes in the CHK pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the CHK or
20 interacting pathways.

Cell-based assays

Cell based assays may detect endogenous CHK pathway activity or may rely on recombinant expression of CHK pathway components. Any of the aforementioned assays
25 may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

Animal Assays

A variety of non-human animal models of normal or defective CHK pathway may
30 be used to test candidate PAK modulators. Models for defective CHK pathway typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the CHK pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, CHK pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal CHK are used to test the candidate modulator's affect on PAK in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the PAK. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

In another preferred embodiment, the effect of the candidate modulator on PAK is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the PAK endogenously are injected in the flank, 1×10^5 to 1×10^7 cells per mouse in a volume of 100 μ L using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

In another preferred embodiment, tumorigenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent,

and evaluating the target cells for reaction to the candidate modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator. Tumorigenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.

In another preferred embodiment, a tumorigenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorigenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

Diagnostic and therapeutic uses

Specific PAK-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the CHK pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention also provides methods for modulating the CHK pathway in a cell, preferably a cell pre-determined to have defective or impaired CHK function (e.g. due to overexpression, underexpression, or misexpression of CHK, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates PAK

activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the CHK function is restored. The phrase "function is restored", and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored CHK function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired CHK function by administering a therapeutically effective amount of a PAK -modulating agent that modulates the CHK pathway. The invention further provides methods for modulating PAK function in a cell, preferably a cell pre-determined to have defective or impaired PAK function, by administering a PAK -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired PAK function by administering a therapeutically effective amount of a PAK -modulating agent.

The discovery that PAK is implicated in CHK pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the CHK pathway and for the identification of subjects having a predisposition to such diseases and disorders.

Various expression analysis methods can be used to diagnose whether PAK expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppe-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective CHK signaling that express a PAK, are identified as amenable to treatment with a PAK modulating agent. In a preferred application, the CHK defective tissue overexpresses a PAK relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial PAK cDNA sequences as probes, can determine whether particular tumors express or overexpress PAK. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of PAK expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

Various other diagnostic methods may be performed, for example, utilizing reagents such as the PAK oligonucleotides, and antibodies directed against a PAK, as

described above for: (1) the detection of the presence of PAK gene mutations, or the detection of either over- or under-expression of PAK mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of PAK gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by PAK.

Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in PAK expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for PAK expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer, most preferably liver, lung, or pancreas cancer. The probe may be either DNA or protein, including an antibody.

EXAMPLES

The following experimental section and examples are offered by way of illustration and not by way of limitation.

I. Drosophila Chk1 screen

The Drosophila Chk1 gene was overexpressed specifically in the eye using the GAL4/UAS system (Brand, A. H. & Perrimon, N. Development (1993) 118:401-415). The glass multimer repeats enhancer was used to drive expression of the GAL4 transcription factor in the eye (GMR-GAL4). GAL4 activated expression of Drosophila Chk1 by initiating transcription from UAS sites contained within a transposon inserted in the first intron of the Chk1 gene (UAS-Chk1). Overexpression of Chk1 in the eye resulted in a G2 cell cycle arrest and a deterioration of general eye morphology. In a screen to identify suppressors and enhancers of Drosophila Chk1, females carrying one copy each of GMR-GAL4 and UAS-Chk1 were crossed to 5300 males carrying random insertions of a piggyBac transposon (Fraser M *et al.*, Virology (1985) 145:356-361). Progeny containing insertions were compared to non-insertion-bearing sibling progeny for enhancement or suppression of the Chk1 phenotype. Sequence information surrounding the piggyBac insertion site was used to identify the modifier genes, which are new members of the Chk1 DNA damage response pathway. fly chk1 was an enhancer of the chk1 phenotype. Orthologs of the modifiers are referred to herein as PAK.

BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of *Drosophila* modifiers. For example, representative sequences from PAK, GI# 7382496 (SEQ ID NO:7), shares 52% amino acid identity with the *Drosophila* fly *chk1*.

Various domains, signals, and functional subunits in proteins were analyzed using the PSORT (Nakai K., and Horton P., Trends Biochem Sci, 1999, 24:34-6; Kenta Nakai, Protein sorting signals and prediction of subcellular localization, Adv. Protein Chem. 54, 277-344 (2000)), PFAM (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2), SMART (Ponting CP, et al., SMART: identification and annotation of domains from signaling and extracellular protein sequences. Nucleic Acids Res. 1999 Jan 1;27(1):229-32), TM-HMM (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998), and clust (Remm M, and Sonnhammer E. Classification of transmembrane protein families in the *Caenorhabditis elegans* genome and identification of human orthologs. Genome Res. 2000 Nov;10(11):1679-89) programs. For example, the kinase domain (PFAM 00069) of PAK from GI# 7382496 (SEQ ID NO:7) is located at approximately amino acid residues 270 to 521.

II. High-Throughput In Vitro Fluorescence Polarization Assay

Fluorescently-labeled PAK peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of PAK activity.

III. High-Throughput In Vitro Binding Assay.

³³P-labeled PAK peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS,

and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate CHK modulating agents.

IV. Immunoprecipitations and Immunoblotting

5 For coprecipitation of transfected proteins, 3×10^6 appropriate recombinant cells containing the PAK proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50
10 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at $15,000 \times g$ for 15 min. The cell lysate is incubated with 25 μ l of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

15 After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence
20 (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

V. Kinase assay

A purified or partially purified PAK is diluted in a suitable reaction buffer, e.g., 50 mM Hepes, pH 7.5, containing magnesium chloride or manganese chloride (1-20 mM) and
25 a peptide or polypeptide substrate, such as myelin basic protein or casein (1-10 μ g/ml). The final concentration of the kinase is 1-20 nM. The enzyme reaction is conducted in microtiter plates to facilitate optimization of reaction conditions by increasing assay throughput. A 96-well microtiter plate is employed using a final volume 30-100 μ l. The reaction is initiated by the addition of ^{33}P -gamma-ATP (0.5 μ Ci/ml) and incubated for 0.5
30 to 3 hours at room temperature. Negative controls are provided by the addition of EDTA, which chelates the divalent cation (Mg^{2+} or Mn^{2+}) required for enzymatic activity. Following the incubation, the enzyme reaction is quenched using EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate (MultiScreen, Millipore). The filters are subsequently washed with phosphate-buffered saline, dilute phosphoric acid

(0.5%) or other suitable medium to remove excess radiolabeled ATP. Scintillation cocktail is added to the filter plate and the incorporated radioactivity is quantitated by scintillation counting (Wallac/Perkin Elmer). Activity is defined by the amount of radioactivity detected following subtraction of the negative control reaction value (EDTA quench).

VI. Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, Stratagene, Ardaïs, Genome Collaborative, and Ambion.

TaqMan analysis was used to assess expression levels of the disclosed genes in various samples.

RNA was extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/μl. Single stranded cDNA was then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

Primers for expression analysis using TaqMan assay (Applied Biosystems, Foster City, CA) were prepared according to the TaqMan protocols, and the following criteria: a) primer pairs were designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis was performed using a 7900HT instrument.

Taqman reactions were carried out following manufacturer's protocols, in 25 μl total volume for 96-well plates and 10 μl total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis was prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be present in appreciable amounts is good. The raw data were normalized using 18S rRNA (universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples were compared with matched normal tissues from the same patient. A gene was considered overexpressed in a tumor when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue was not available, a universal

pool of cDNA samples was used instead. In these cases, a gene was considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., Tumor – average(all normal samples) > 2 x STDEV(all normal samples)).

PAK GI# 7382495 (SEQ ID NO:1) was overexpressed in liver cancer(60% of 5 matched samples), lung cancer (31% of 35 matched samples), and pancreas cancer (78% of 9 matched samples). A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

VII. PAK functional assays

RNAi experiments were carried out to knock down expression of PAK (SEQ ID NO:1) in various cell lines using small interfering RNAs (siRNA, Elbashir et al, *supra*).

Effect of PAK RNAi on cell proliferation and growth. BrdU and Cell Titer-Glo™ assays, as described above, were employed to study the effects of decreased PAK expression on cell proliferation. The results of these experiments indicated that RNAi of PAK decreases proliferation in MCF7 breast cancer cell lines. MCF7 line is an estrogen receptor positive line. MTS cell proliferation assay, as described above, was also employed to study the effects of decreased PAK expression on cell proliferation. The results of this experiment indicated that RNAi of PAK decreased proliferation in LX1 small cell lung cancer cells.

Effect of PAK RNAi on cell cycle. Propidium iodide (PI) cell cycle assay, as described above, was employed to study the effects of decreased PAK expression on cell cycle. Decreased PAK expression caused an increased sub G1 region in LX1 cells. The region of subG1 represents cells undergoing apoptosis-associated DNA degradation

PAK overexpression analysis. PAK (SEQ ID NO:1) was overexpressed and tested in colony growth assays as described above. Overexpressed PAK had no morphological

effects on cells, and moderate effects on colony growth. Effects of overexpressed PAK on expression of various transcription factors was also studied. Overexpressed PAK caused an increased expression of the following transcription factors: EGR, ETS1, E2F, and CREB.

WHAT IS CLAIMED IS:

1. A method of identifying a candidate CHK pathway modulating agent, said method comprising the steps of:

- 5 (a) providing an assay system comprising a PAK polypeptide or nucleic acid;
 (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
 (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as
10 a candidate CHK pathway modulating agent.

2. The method of Claim 1 wherein the assay system comprises cultured cells that express the PAK polypeptide.

- 15 3. The method of Claim 2 wherein the cultured cells additionally have defective CHK function.

4. The method of Claim 1 wherein the assay system includes a screening assay comprising a PAK polypeptide, and the candidate test agent is a small molecule
20 modulator.

5. The method of Claim 4 wherein the assay is a kinase assay.

6. The method of Claim 1 wherein the assay system is selected from the group consisting
25 of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.

7. The method of Claim 1 wherein the assay system includes a binding assay comprising a PAK polypeptide and the candidate test agent is an antibody.
30

8. The method of Claim 1 wherein the assay system includes an expression assay comprising a PAK nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of Claim 8 wherein the nucleic acid modulator is an antisense oligomer.

10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.

11. The method of Claim 1 additionally comprising:

5 (d) administering the candidate CHK pathway modulating agent identified in (c) to a model system comprising cells defective in CHK function and, detecting a phenotypic change in the model system that indicates that the CHK function is restored.

12. The method of Claim 11 wherein the model system is a mouse model with defective CHK function.

10

13. A method for modulating a CHK pathway of a cell comprising contacting a cell defective in CHK function with a candidate modulator that specifically binds to a PAK polypeptide, whereby CHK function is restored.

15 14. The method of Claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in CHK function.

20 15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

16. The method of Claim 1, comprising the additional steps of:

(e) providing a secondary assay system comprising cultured cells or a non-human animal expressing PAK ,

25 (f) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and

(g) detecting an agent-biased activity of the second assay system,

30 wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate CHK pathway modulating agent,

and wherein the second assay detects an agent-biased change in the CHK pathway.

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-human
5 animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses a CHK pathway gene.

10 20. A method of modulating CHK pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a PAK polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the CHK pathway.

15

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:

20

- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with a probe for PAK expression;
- (c) comparing results from step (b) with a control;
- (d) determining whether step (c) indicates a likelihood of disease.

25 24. The method of Claim 23 wherein said disease is cancer.

25. The method according to Claim 24, wherein said cancer is liver, lung, or pancreas cancer.

30

SEQUENCE LISTING

<110> EXELIXIS, INC.

<120> PAKS AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE

<130> EX03-067C-PC

<150> US 60/410,986

<151> 2002-09-16

<160> 7

<170> PatentIn version 3.2

<210> 1

<211> 2318

<212> DNA

<213> Homo sapiens

<400> 1

gccacgaagg ccacagacgc cttccccctt ggactctcat tcccttttcc acggagcccc	60
gcgctttcgt gagccccctc gaggaacctg gtctccgcat ccagttacca cctcctgcct	120
cagaggccat ctgagccctt cgcacctcgc ccctcagtc ccccttgccc ccccgaggag	180
atgcctcgc tccctcccg cccccatca tcccttcctt cgcagttccc ctgtcctgag	240
gggagccccg ccacggcagc gacagcgggc aggagggaga aagtgaaggt tgggcgacac	300
ttggcctcac tcccggttag ggcgacccac ggggaggaga ggaggagccg agagagctga	360
gcagcgcgga agtagctgct gctgggtggtg acaatgtcaa ataacggcct agacattcaa	420
gacaaacccc cagccccctc gatgagaaat accagcacta tgattggagt cggcagcaaa	480
gatgctggaa ccctaaacca tggttctaaa cctctgcctc caaacccaga ggagaagaaa	540
aagaaggacc gattttaccg atccatttta cctggagata aaacaaataa aaagaaagag	600
aaagagcggc cagagatttc tctcccttca gattttgaac acacaattca tgtcggtttt	660
gatgctgtca caggggagtt tacgggaatg ccagagcagt gggcccgctt gcttcagaca	720
tcaaatatca ctaagtcgga gcagaagaaa aaccgcagg ctgttctgga tgtgttgag	780
ttttacaact cgaagaagac atccaacagc cagaaataca tgagctttac agataagtca	840
gctgaggatt acaattcttc taatgccttg aatgtgaagg ctgtgtctga gactcctgca	900
gtgccaccag tttcagaaga tgaggatgat gatgatgatg atgctacccc accaccagtg	960
attgctccac gccagagca cacaaaatct gtatacacac ggtctgtgat tgaaccactt	1020
cctgtcactc caactcggga cgtggctaca tctccpattt cacctactga aaataacacc	1080
actccaccag atgctttgac ccggaatact gagaagcaga agaagaagcc taaaatgtct	1140
gatgaggaga tcttgagaa attacgaagc atagtgagtg tgggcgatcc taagaagaaa	1200
tatacacggt ttgagaagat tggacaaggt gcttcaggca ccgtgtacac agcaatggat	1260

gtggccacag gacaggaggt ggccattaag cagatgaatc ttcagcagca gccaagaaa 1320
 gagctgatta ttaatgagat cctgggtcatg agggaaaaca agaaccctaaa cattgtgaat 1380
 tacttggaca gttacctcgt gggagatgag ctgtgggttg ttatggaata cttggctgga 1440
 ggctccttga cagatgtggt gacagaaact tgcattgatg aaggccaaat tgcagctgtg 1500
 tgccgtgagt gtctgcaggc tctggagttc ttgcattcga accagggtcat tcacagagac 1560
 atcaagagtg acaatattct gttgggaatg gatgggtctg tcaagctaac tgactttgga 1620
 ttctgtgcac agataacccc agagcagagc aaacggagca ccatggtagg aacccctac 1680
 tggatggcac cagaggttgt gacacgaaag gcctatgggc ccaagggtga catctgggtcc 1740
 ctgggcatca tggccatcga aatgattgaa ggggagcctc catacctcaa tgaaaaccct 1800
 ctgagagcct tgtacctcat tgccaccaat gggaccccag aacttcagaa cccagagaag 1860
 ctgtcagcta tcttcggga ctttctgaac cgctgtctcg atatggatgt ggagaagaga 1920
 gggtcagcta aagagctgct acagcatcaa ttctgaaga ttgccaagcc cctctccagc 1980
 ctcaactccac tgattgctgc agctaaggag gcaacaaaga acaatcacta aaaccacact 2040
 caccagcc tcattgtgcc aagctctgtg agataaatgc acatttcaga aattccaact 2100
 cctgatgcc tcttctcctt gccttgcttc tccatttcc tgatctagca ctctcaaga 2160
 ctttgatcct tggaaaccgt gtgtccagca ttgaagagaa ctgcaactga atgactaatc 2220
 agatgatggc catttctaaa taaggaattt cctcccaatt catggatatg aggggtggtt 2280
 atgattaagg gtttatataa ataatgttt ctagtctt 2318

<210> 2

<211> 2023

<212> DNA

<213> Homo sapiens

<400> 2

atggatagaa tgggtgctatc tgagctgtta taatgttggc ctcatgccta gctttatatt 60
 gcagcacgtc tgaggcattg gtttttcatc ctccaaact tttggtctac agagactatt 120
 agaagattaa gtagctgctg ctggtggtga caatgtcaaa taacggccta gacattcaag 180
 acaaaccccc agcccctccg atgagaaata ccagcactat gattggagcc ggcagcaaag 240
 atgctggaac cctaaaccat ggttctaaac ctctgcctcc aaaccagag gagaagaaaa 300
 agaaggaccg attttaccga tccattttac ctggagataa aacaaataaa aagaaagaga 360
 aagagcggcc agagatttct ctcccttcag attttgaaca cacaattcat gtcgggtttg 420
 atgctgtcac aggggagttt acgggaatgc cagagcagtg ggcccgttg cttcagacat 480
 caaatatcac taagtcggag cagaagaaaa acccgaggc tgttctggat gtgttggagt 540

ttacaactc gaagaagaca tccaacagcc agaaatacat gagctttaca gataagtcag 600
 ctgaggatta caattcttct aatgccttga atgtgaaggc tgtgtctgag actcctgcag 660
 tgccaccagt ttcagaagat gaggatgatg atgatgatga tgctacccca ccaccagtga 720
 ttgctccacg cccagagcac acaaaatctg tatacacacg gtctgtgatt gaaccacttc 780
 ctgtcactcc aactcgggac gtggctacat ctcccatttc acctactgaa aataacacca 840
 ctccaccaga tgctttgacc cggaatactg agaagcagaa gaagaagcct aaaatgtctg 900
 atgaggagat cttggagaaa ttacgaagca tagtgagtgt gggcgatcct aagaagaaat 960
 atacacgggt tgagaagatt ggacaagggtg cttcaggcac cgtgtacaca gcaatggatg 1020
 tggccacagg acaggaggtg gccattaagc agatgaatct tcagcagcag cccaagaaag 1080
 agctgattat taatgagatc ctgggtcatga gggaaaacaa gaacccaaac atttgtgaatt 1140
 acttggacag ttacctcgtg ggagatgagc tgtgggttgt tatggaatac ttggctggag 1200
 gctccttgac agatgtgggtg acagaaactt gcatggatga aggccaaatt gcagctgtgt 1260
 gccgtgagtg tctgcaggct ctggagttct tgcattcgaa ccaggtcatt cacagagaca 1320
 tcaagagtga caatattctg ttgggaatgg atggctctgt caagctaact gactttggat 1380
 tctgtgcaca gataacccca gagcagagca aacggagcac catggtagga accccatact 1440
 ggatggcacc agaggttgtg acacgaaagg cctatgggcc caagggtgac atctgggtccc 1500
 tgggcatcat ggccatcgaa atgattgaag gggagcctcc atacctcaat gaaaaccctc 1560
 tgagagcctt gtacctcatt gccaccaatg ggacccaga acttcagaac ccagagaagc 1620
 tgtcagctat cttccgggac tttctgaacc gctgtctcga gatggatgtg gagaagagag 1680
 gttcagctaa agagctgcta cagggtgagaa aactgaggtt tcaagtgttt agtaactttt 1740
 ccatgatagc tgcattcaatt cctgaagatt gccaagcccc tctccagcct cactccactg 1800
 attgctgcag ctaaggaggc aacaaagaac aatcactaaa accacactca cccagcctc 1860
 attgtgccaa gccttctgtg agataaatgc acatttcaga aattccaact cctgatgccc 1920
 tcttctcctt gccttgcttc tcccatttcc tgatctagca ctctcaaga ctttgcctct 1980
 tggaaaccgt gtgtccagca ttgaagagaa ctgcaactga atg 2023

<210> 3
 <211> 1880
 <212> DNA
 <213> Homo sapiens

<400> 3
 tgggtgggtgac aatgtcaaata aacggcctag acattcaaga caaaccacca gccctccga 60
 tgagaaatac cagcactatg attggagtcg gcagcaaaga tgctggaacc ctaaaccatg 120
 gttctaaacc tctgcctcca aaccagagg agaagaaaaa gaaggaccga ttttaccgat 180

ccattttacc tggagataaa acaaataaaa agaaagagaa agagcggcca gagattttctc 240
 tcccttcaga ttttgaacac acaattcatg tccggttttga tgctgtcaca ggggagttta 300
 cgggaatgcc agagcagtgg gcccgcttgc ttcagacatc aaatatcact aagtcggagc 360
 agaagaaaaa cccgcaggct gttctggatg tgttggagtt ttacaactcg aagaagacat 420
 ccaacagcca gaaatacatg agctttacag ataagtcagc tgaggattac aattcttcta 480
 atgccttgaa tgtgaaggct gtgtctgaga ctctgcagc gccaccagtt tcagaagatg 540
 aggatgatga tgatgatgat gctacccac caccagtgtg tgctccacgc ccagagcaca 600
 caaaatctgt atacacacgg tctgtgattg aaccacttcc tgtcactcca actcgggacg 660
 tggctacatc tcccatttca cctactgaaa ataacaccac tccaccagat gctttgacct 720
 ggaatactga gaagcagaag aagaagccta aaatgtctga tgaggagatc ttggagaaat 780
 tacgaagcat agtgagtgtg ggcgatccta agaagaaata tacacggttt gagaagattg 840
 gacaagggtc ttcaggcacc gtgtacacag caatggatgt ggccacagga caggaggtgg 900
 ccattaagca gatgaatctt cagcagcagc ccaagaaaga gctgattatt aatgagatcc 960
 tgggtcatgag ggaaaacaag aacccaaaca ttgtgaatta cttggacagt tacctcgtgg 1020
 gagatgagct gtgggttgtt atggaatact tggctggagg ctcttgaca gatgtggtga 1080
 cagaaacttg catggatgaa ggccaaattg cagctgtgtg ccgtgagtgt ctgcaggctc 1140
 tggagtctct gcattcgaac caggctattc acagagacat caagagtgc aatattctgt 1200
 tgggaatgga tggctctgtc aagctaactg actttggatt ctgtgcacag ataaccacag 1260
 agcagagcaa acggagcacc atggtaggaa ccccatactg gatggcacca gaggttgtga 1320
 cacgaaaggc ctatgggccc aagggtgaca tctggtccct gggcatcatg gccatcgaaa 1380
 tgattgaagg ggagcctcca tacctcaatg aaaaccctct gagagccttg tacctcattg 1440
 ccaccaatgg gacccagaa cttcagaacc cagagaagct gtcagctatc ttccgggact 1500
 ttctgaaccg ctgtctcgag atggatgtgg agaagagagg ttcagctaaa gagctgctac 1560
 aggtgagaaa actgagggtt caagtgttta gtaacttttc catgatagct gcatcaattc 1620
 ctgaagattg ccaagccct ctccagcctc actccactga ttgctgcagc taaggaggca 1680
 acaaagaaca atcactaaaa ccacactcac cccagcctca ttgtgccaag ctctgtgaga 1740
 taaatgcaca tttcagaaat tccaactcct gatgccctct tctccttgcc ttgcttctcc 1800
 catttcctga tctagcactc ctcaagactt tgatccttgg aaaccgtgtg tccagcattg 1860
 aagagaactg caactgaatg 1880

<210> 4

<211> 2889

<212> DNA

<213> Homo sapiens

<400> 4

gagagcgcca gcggtgctgca cctcggggagc tggcggtgga gctgccagga gccacagcca	60
gctgaatcga gcggagccgg tggagcaggg gccttggtggg taccgggttg ggcagggaga	120
ggtgctggctc tgcgacggaa acaatcgcca gagatgccgg ggctagcctt cccaccagt	180
agctgctgct ggtggtgaca atgtcaaata acggcctaga cattcaagac aaacccccag	240
cccctccgat gagaaatacc agcactatga ttggagccgg cagcaaagat gctggaaccc	300
taaaccatgg ttctaaacct ctgcctcaa acccagagga gaagaaaaag aaggaccgat	360
tttaccgatc cattttacct ggagataaaa caaataaaaa gaaagagaaa gagcggccag	420
agattttctc cccttcagat tttgaacaca caattcatgt cggttttgat gctgtcacag	480
gggagtttac gggaatgccca gagcagtggg cccgcttgct tcagacatca aatatcacta	540
agtcggagca gaagaaaaac ccgcaggctg ttctggatgt gttggagtgt tacaactcga	600
agaagacatc caacagccag aaatacatga gctttacaga taagtcagct gaggattaca	660
attcttctaa tgccttgaat gtgaaggctg tgtctgagac tcctgcagtg ccaccagttt	720
cagaagatga ggatgatgat gatgatgatg ctacccacc accagtgatt gctccacgcc	780
cagagcacac aaaatctgta tacacacggg ctgtgattga accacttcct gtcactcaa	840
ctcgggacgt ggctacatct cccatttcac ctactgaaaa taacaccact ccaccagatg	900
ctttgacccg gaatactgag aagcagaaga agaagcctaa aatgtctgat gaggagatct	960
tggagaaatt acgaagcata gtgagtgtgg gcgaccta gaagaaatat acacggtttg	1020
agaagattgg acaaggtgct tcaggcaccg tgtacacagc aatggatgtg gccacaggac	1080
aggaggtggc cattaagcag atgaatcttc agcagcagcc caagaaagag ctgattatta	1140
atgagatcct ggtcatgagg gaaaacaaga acccaaacat tgtgaattac ttggacagtt	1200
acctcgtggg agatgagctg tgggttgta tggaatactt ggctggaggc tccttgacag	1260
atgtggtgac agaaacttgc atggatgaag gccaaattgc agctgtgtgc cgtgagtgtc	1320
tgcaggctct ggagttcttg cattcgaacc aggtcattca cagagacatc aagagtgaca	1380
atattctgtt gggaatggat ggctctgtca agctaactga ctttggattc tgtgcacaga	1440
taaccccaga gcagagcaaa cggagcacca tggtaggaac ccatactgg atggcaccag	1500
aggttggtgac acgaaaggcc tatgggccca aggttgacat ctggtccttg ggcacatgg	1560
ccatcgaaat gattgaaggg gagcctccat acctcaatga aaaccctctg agagccttgt	1620
acctcattgc caccaatggg accccagaac ttcagaaccc agagaagctg tcagctatct	1680
tccgggactt tctgaaccgc tgtctcgaga tggatgtgga gaagagaggt tcagctaaag	1740

agctgctaca gcactcctca agactttgat ccttggaac cgtgtgtcca gcattgaaga 1800
 gaactgcaac tgaatgacta atcagatgat ggccatttct aaataaggaa tttcctccca 1860
 attcatggat atgaggggtgg tttatgatta aggggtttata laaataaatg tttctagtct 1920
 tccgtgtgtc aaaatcctca cctccttcat aaccatctcc cacaattaat tcttgactat 1980
 ataaatttat ggtttgataa tattatcaat ttgtaatcaa ttgagatttc tttagtgtt 2040
 gcttttctgt gactcaactg ccagacacc tcattgtact tgaaaactgg aacagcttgg 2100
 gaatgccatg gggtttgata atctgccagg gacatgaaga ggctcagctt cctggaccat 2160
 gactttggct cagctgatcc tgacatggga gaacaaccac atttttcttt gtgtgtgtt 2220
 ctagcagctg ttcgggagga ccttgacca acagtgttcc catgctgttt cttgtgaaat 2280
 gctctcggct atgtagcagc ttttgattcc ctgcataccc taggctgtg cccctatcct 2340
 gtcccttgtt tataacattg agaggttttc tagggcacat actgagttag agcagtgtt 2400
 agaagtcggg gaaaatgggtg actactttta gagcaaggct gggcatcagc acctgtccag 2460
 ctctacttgt gtgatgtttc aggaactcag cccctttttc tgcctaggat aaggagctga 2520
 aagattaact tggatcttct aatgggtccaa atcttttggc cacaataaag agtctccaaa 2580
 ttagagactg catgttagtt ctggatggat ttggtggcct gacatgatac cctgccagct 2640
 gtgaggggac cccgttttta agatgcatgg ctaagctctc tgcaaagga aatgcttaca 2700
 ctgggtgttg gggatgtttg ctacctctg ctatttttgt ggttttgggt ctcccactat 2760
 ggtaggacct ctggccagca ttgtggcttg tcatgtcagc cccattgact acctctcat 2820
 gctctgaggt actactgcct ctgcagcaca aatttctatt tctgtcaata aaaggagatg 2880
 aaaatatc 2889

<210> 5
 <211> 1740
 <212> DNA
 <213> Homo sapiens

<400> 5
 ggagagccga gaggagctga gcgagcgcg aagtagctgc tgctgggtgg gacaatgtca 60
 aataacggcc tagacattca agacaaacct ccagcccctc cgatgagaaa taccagcact 120
 atgattggag ccggcagcaa agatgctgga accctaaacc atgggttctaa acctctgcct 180
 ccaaaccag aggagaagaa aaagaaggac cgattttacc gatccatttt acctggagat 240
 aaaacaaata aaaagaaaga gaaagagcgg ccagagattt ctctcccttc agattttgaa 300
 cacacaattc atgtcgggtt tgatgctgtc acaggggagt ttaccggaat gccagagcag 360
 tgggcccgtg tgcttcagac atcaaatac actaagtcgg agcagaagaa aaaccgcag 420
 gctgttctgg atgtgttga gttttacaac tcgaagaaga catccaacag ccagaaatac 480

atgagcttta cagataagtc agctgaggat tacaattctt ctaatgcctt gaatgtgaag 540
gctgtgtctg agactcctgc agtgccacca gtttcagaag atgaggatga tgatgatgat 600
gatgctaccc caccaccagt gattgctcca cgcccagagc acacaaaatc tgtatacaca 660
cgggtctgtga ttgaaccact tcctgtcact ccaactcggg acgtggctac atctccatt 720
tcacctactg aaaataacac cactccacca gatgctttga cccttaatac tgagaagcag 780
aagaagaagc ctaaaatgtc tgatgaggag atcttgagaga aattacgaag catagtgaag 840
gtgggcgatc ctaagaagaa atatacacgg tttgagaaga ttggacaagg tgcttcaggc 900
accgtgtaca cagcaatgga tgtggccaca ggacaggagg tggcattaa gcagatgaat 960
cttcagcagc agcccaagaa agagctgatt attaatgaga tcctggcat gagggaaaac 1020
aagaacccaa acattgtgaa ttacttgac agttacctg tgggagatga gctgtgggtt 1080
gttatggaat acttggtgg aggtccttg acagatgtgg tgacagaaac ttgcatggat 1140
gaaggccaaa ttgcagctgt gtgccgtgag tgtctgcagg ctctggagtc tttgcattcg 1200
aaccaggtca ttcacagaga catcaagagt gacaatatc tgttgggaat ggatggctct 1260
gtcaagctaa ctgactttgg attctgtgca cagataacc cagagcagag caaacggagc 1320
accatggtag gaaccccata ctggatggca ccagagggtg tgacacgaaa ggcctatggg 1380
ccaaggttg acatctggtc cctgggcac atggccatcg aaatgattga aggggagcct 1440
ccatacctca atgaaaacc tctgagagcc ttgtacctca ttgccaccaa tgggacccca 1500
gaacttcaga acccagagaa gctgtcagct atcttccggg actttctgaa ccgctgtctc 1560
gagatggatg tggagaagag aggttcagct aaagagctgc tacagcatca attcctgaag 1620
attgccaaag ccctctccag cctcactcca ctgattgctg cagctaagga ggcaacaaag 1680
aacaatcact aaaaccacac tcacccagc ctcatgtgc caagccttct gtgagataaa 1740

<210> 6

<211> 2134

<212> DNA

<213> Homo sapiens

<400> 6

acctcgggag ctggcggctg agctgccagg agcccagccc agctgaatcg agcggagccg 60
gtggagcagg ggccttgtgg gtacccggtt gggcaggag aggtgcggct ctgcgacgga 120
aacaatcgcc agagatgccg gggctagcct tccccaccag gttggtggcg atacaaaaat 180
tgaaactggc ctcatgtgtt gctctcaaat gcagatcaag gaatgtggac gctcatgtga 240
gtagctgctg ctggtgtgta caatgtcaaa taacggccta gacattcaag acaaaccccc 300
agcccctccg atgagaaata ccagcactat gattggagcc ggcagcaaag atgctggaac 360

cctaaacat ggttctaaac ctctgcctcc aaaccagag gagaagaaa agaaggaccg 420
atattaccga tccattttac ctggagataa aacaaataaa aagaaagaga aagagcggcc 480
agagattttct ctcccttcag attttgaaca cacaattcat gtcgyltttg atgctgtcac 540
aggggagttt acggggaatg ccagagcagt gggcccgctt gcttcagaca tcaaatatca 600
ctaagtcgga gcagaagaaa aaccgcgagg ctgttctgga tgtgttgagg ttttacaact 660
cgaagaagac atccaacagc cagaaatata tgagctttac agataagtca gctgaggatt 720
acaattcttc taatgccttg aatgtgaagg ctgtgtctga gactcctgca gtgccaccag 780
tttcagaaga tgaggatgat gatgatgatg atgctacccc accaccagtg attgctccac 840
gccagagca caaaaatct gtatacacac ggtctgtgat tgaaccactt cctgtcactc 900
caactcgga cgtggctaca tctccattt cacctactga aaataacacc actccaccag 960
atgctttgac ccggaatact gagaagcaga agaagaagcc taaaatgtct gatgaggaga 1020
tcttgagaa attacgaagc atagtgaagt tgggcgatcc taagaagaaa tatacacggt 1080
ttgagaagat tggacaaggt gcttcaggca ccgtgtacac agcaatggat gtggccacag 1140
gacaggaggt ggccattaag cagatgaatc ttcagcagca gcccaagaaa gagctgatta 1200
ttaatgagat cctggtcagt agggaaaaca agaaccctaa cattgtgaat tacttggaca 1260
gttacctcgt gggagatgag ctgtgggttg ttatggaata cttggctgga ggctccttga 1320
cagatgtggt gacagaaact tgcattggatg aaggccaaat tgcagctgtg tgccgtgagt 1380
gtctgcaggc tctggagttc ttgcattcga accagggtcat tcacagagac atcaagagtg 1440
acaatattct gttgggaatg gatggctctg tcaagctaac tgactttgga ttctgtgcac 1500
agataacccc agagcagagc aaacggagca ccatggtagg aaccctatac tggatggcac 1560
cagaggttgt gacacgaaag gcctatgggc ccaagggtga catctgggtc ctgggcatca 1620
tgccatcga aatgattgaa ggggagcctc catacctcaa tgaaaaccct ctgagagcct 1680
tgtacctcat tgccaccaat gggaccccag aacttcagaa cccagagaag ctgtcagcta 1740
tcttcggga ctttctgaac cgctgtctcg agatggatgt ggagaagaga ggttcagcta 1800
aagagctgct acaggtgaga aaactgaggt ttcaagtgt tagtaacttt tccatgatag 1860
ctgcatcaat tctgaagat tgccaagccc ctctccagcc tactccact gattgctgca 1920
gctaaggagg caacaaagaa caatcactaa aaccacactc acccagcct cattgtgcca 1980
agccttctgt gagataaatg cacatttcag aaattccaac tctgatgcc ctcttctcct 2040
tgcttgcct ctccatttc ctgatctagc actcctcaag actttgatcc ttggaaaccg 2100
tgtgtccagc attgaagaga actgcaactg aatg 2134

<211> 545
 <212> PRT
 <213> Homo sapiens

<400> 7

Met Ser Asn Asn Gly Leu Asp Ile Gln Asp Lys Pro Pro Ala Pro Pro
 1 5 10 15

Met Arg Asn Thr Ser Thr Met Ile Gly Val Gly Ser Lys Asp Ala Gly
 20 25 30

Thr Leu Asn His Gly Ser Lys Pro Leu Pro Pro Asn Pro Glu Glu Lys
 35 40 45

Lys Lys Lys Asp Arg Phe Tyr Arg Ser Ile Leu Pro Gly Asp Lys Thr
 50 55 60

Asn Lys Lys Lys Glu Lys Glu Arg Pro Glu Ile Ser Leu Pro Ser Asp
 65 70 75 80

Phe Glu His Thr Ile His Val Gly Phe Asp Ala Val Thr Gly Glu Phe
 85 90 95

Thr Gly Met Pro Glu Gln Trp Ala Arg Leu Leu Gln Thr Ser Asn Ile
 100 105 110

Thr Lys Ser Glu Gln Lys Lys Asn Pro Gln Ala Val Leu Asp Val Leu
 115 120 125

Glu Phe Tyr Asn Ser Lys Lys Thr Ser Asn Ser Gln Lys Tyr Met Ser
 130 135 140

Phe Thr Asp Lys Ser Ala Glu Asp Tyr Asn Ser Ser Asn Ala Leu Asn
 145 150 155 160

Val Lys Ala Val Ser Glu Thr Pro Ala Val Pro Pro Val Ser Glu Asp
 165 170 175

Glu Asp Asp Asp Asp Asp Ala Thr Pro Pro Pro Val Ile Ala Pro
 180 185 190

Arg Pro Glu His Thr Lys Ser Val Tyr Thr Arg Ser Val Ile Glu Pro
 195 200 205

Leu Pro Val Thr Pro Thr Arg Asp Val Ala Thr Ser Pro Ile Ser Pro
 210 215 220

Thr Glu Asn Asn Thr Thr Pro Pro Asp Ala Leu Thr Arg Asn Thr Glu
 225 230 235 240
 Lys Gln Lys Lys Lys Pro Lys Met Ser Asp Glu Glu Ile Leu Glu Lys
 245 250 255
 Leu Arg Ser Ile Val Ser Val Gly Asp Pro Lys Lys Lys Tyr Thr Arg
 260 265 270
 Phe Glu Lys Ile Gly Gln Gly Ala Ser Gly Thr Val Tyr Thr Ala Met
 275 280 285
 Asp Val Ala Thr Gly Gln Glu Val Ala Ile Lys Gln Met Asn Leu Gln
 290 295 300
 Gln Gln Pro Lys Lys Glu Leu Ile Ile Asn Glu Ile Leu Val Met Arg
 305 310 315 320
 Glu Asn Lys Asn Pro Asn Ile Val Asn Tyr Leu Asp Ser Tyr Leu Val
 325 330 335
 Gly Asp Glu Leu Trp Val Val Met Glu Tyr Leu Ala Gly Gly Ser Leu
 340 345 350
 Thr Asp Val Val Thr Glu Thr Cys Met Asp Glu Gly Gln Ile Ala Ala
 355 360 365
 Val Cys Arg Glu Cys Leu Gln Ala Leu Glu Phe Leu His Ser Asn Gln
 370 375 380
 Val Ile His Arg Asp Ile Lys Ser Asp Asn Ile Leu Leu Gly Met Asp
 385 390 395 400
 Gly Ser Val Lys Leu Thr Asp Phe Gly Phe Cys Ala Gln Ile Thr Pro
 405 410 415
 Glu Gln Ser Lys Arg Ser Thr Met Val Gly Thr Pro Tyr Trp Met Ala
 420 425 430
 Pro Glu Val Val Thr Arg Lys Ala Tyr Gly Pro Lys Val Asp Ile Trp
 435 440 445
 Ser Leu Gly Ile Met Ala Ile Glu Met Ile Glu Gly Glu Pro Pro Tyr
 450 455 460
 Leu Asn Glu Asn Pro Leu Arg Ala Leu Tyr Leu Ile Ala Thr Asn Gly
 465 470 475 480

Thr Pro Glu Leu Gln Asn Pro Glu Lys Leu Ser Ala Ile Phe Arg Asp
485 490 495

Phe Leu Asn Arg Cys Leu Asp Met Asp Val Glu Lys Arg Gly Ser Ala
500 505 510

Lys Glu Leu Leu Gln His Gln Phe Leu Lys Ile Ala Lys Pro Leu Ser
515 520 525

Ser Leu Thr Pro Leu Ile Ala Ala Ala Lys Glu Ala Thr Lys Asn Asn
530 535 540

His
545

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024883 A3

(51) International Patent Classification⁷: **G01N 33/00**,
A61K 49/00

(21) International Application Number:
PCT/US2003/028904

(22) International Filing Date:
15 September 2003 (15.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/410,986 16 September 2002 (16.09.2002) US

(71) Applicant (*for all designated States except US*): **EX-
ELIXIS, INC.** [US/US]; P.O. Box 511, 170 Harbor Way,
South San Francisco, CA 94083-0511 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FRANCIS-LANG**,
Helen [GB/US]; 1782 Pacific Avenue, Apt. 2, San Fran-
cisco, CA 94109 (US). **ROCHE**, **Siobhan** [IE/IE]; 30
Moatfield Park, Coolock, Dublin 5 (IE). **LICKTEIG**,
Klm [US/US]; 1921 Grove Street, San Francisco, CA
94117 (US).

(74) Agents: **SHAYESTEH**, **Laleh et al.**; Exelixis, Inc., P.O.
Box 511, 170 Harbor Way, South San Francisco, CA
94083-0511 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(88) Date of publication of the international search report:
24 June 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE**

(57) Abstract: Human PAK genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of PAK are provided.

WO 2004/024883 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/28904

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : G01N 33/00; A61K 49/00

US CL : 800/3; 424/9.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 800/3; 424/9.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST, MEDLINE, BIOSIS, EMBASE, SCISEARCH, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GRILL B. et al. Activation of Rac-1, Rac-2, and Cdc42 by hemopoietic growth factors or cross-linking of the B-lymphocyte receptor for antigen. Blood. 01 November 2002, Vol. 100, No. 9, pages 3183-3192, see entire document.	1-25
A	KIM S. et al. Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer. The Journal of Biological Chemistry. 27 September 2002, Vol. 277, No. 39, pages 36465-36470, see entire document.	1-25
A	ROONEY R. D. et al. Cleavage arrest of early frog embryos by the G protein-activated protein kinase PAK1. The Journal of Biological Chemistry. 30 August 1996, Vol. 271, No. 35, pages 21498-21504, see entire document.	1-25
A	TAKAI H. et al. Chk2 deficient mice exhibit radioresistance and defective p53-mediated transcription. The EMBO Journal. 2002, Vol. 21, No. 19, pages 5195-5205, see entire document.	1-25

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

23 February 2004 (23.02.2004)

Date of mailing of the international search report

07 MAY 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Peter Paras, Jr.

Telephone No. 703-308-0196